نتایج جستجو برای: Bypassing agents

تعداد نتایج: 363754  

Ardeshiri, Rezvan , Fasih, Belgheis , Habibpanah, Behnaz , Malek, Fatemeh , Managhchi, Mohammad Reza , Salimi, Tahmineh , Tara, Zahra ,

Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the...

Journal: :iranian journal of blood and cancer 0
behnaz habibpanah pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences) zahra tara pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences) fatemeh malek pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences) rezvan ardeshiri shahid dastgheib hemophilia center. shiraz university of medical sciences, shiraz, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (shiraz university of medical sciences) tahmineh salimi comprehensive hemophilia care center, iran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (iran university of medical sciences) belgheis fasih aliasghar hospital, zahedan university of medical sciences, zahedan, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی زاهدان (zahedan university of medical sciences)

background: bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. currently available agents in iran are recombinant activated factor vii (rfviia; aryogen, aryoseven) and feiba (factor eight inhibitor bypassing agent). no standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. we suggested that history of the...

Journal: :iranian journal of pharmaceutical sciences 0
abdol majid cheraghali bms university mina golestani 1school of pharmacy, shahid beheshti university of medical sciences, tehran, ir iran, iranian center of excellence in health management peyman eshghi 2pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, ir iran, [email protected] hamidreza rasekh 4school of pharmacy, shahid beheshti university of medical sciences, tehran, ir iran, [email protected] jamshid salamzadeh 5school of pharmacy, shahid beheshti university of medical sciences, tehran, ir iran,[email protected] ali imani 6iranian center of excellence in health management, faculty of management and medical informatics, tabriz university of medical sciences, tabriz, ir iran, [email protected]

bypassing agents are the most commonly used medicines for the treatment of hemophilia patients with inhibitors. the aim of this study is to identify the cost components of management of bleeding vents in hemophilia patients with inhibitors in iran. this study is a cross-sectional study using a bottom-up approach to determine the cost components of treatment of hemophilia patients with inhibitor...

Journal: :anesthesiology and pain medicine 0
yashar ilkhchoui department of anesthesiology and critical care medicine, school of medicine, university of new mexico, albuquerque, usa; department of anesthesiology and critical care medicine, school of medicine, university of new mexico, albuquerque, nm, usa. tel: +1-5052722610, fax: +1-5052721300 eugene koshkin department of anesthesiology and critical care medicine, school of medicine, university of new mexico, albuquerque, usa jimmy j windsor department of anesthesiology and critical care medicine, school of medicine, university of new mexico, albuquerque, usa timothy r petersen department of anesthesiology and critical care medicine, school of medicine, university of new mexico, albuquerque, usa matthew charles department of anesthesiology and critical care medicine, school of medicine, university of new mexico, albuquerque, usa jeffery d pack department of anesthesiology and critical care medicine, school of medicine, university of new mexico, albuquerque, usa

conclusions treatment strategies in acquired hemophilia are based on two major objectives. during the acute stage, effective control of bleeding is critical. the ultimate therapeutic goal during the subacute phase is the elimination of the inhibitors targeting factor viii. here, we present this case and will review current literature regarding therapeutic approaches to this rare condition in th...

2015
Hee Young Ju Hye Lim Jang Young Shil Park

BACKGROUND Inhibitory antibodies to factor VIII (FVIII) or IX (FIX) are important issues when managing patients with hemophilia A or B. Advances in bypassing agents such as recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (APCC) have enabled the aggressive management of hemophilia with inhibitors during emergency or elective surgery. This study provides an upda...

2011
Linda Butros Koh Boayue Prasad Mathew

Bypassing agents are the mainstay of treatment for patients with hemophilia with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes in this population, timely administration of bypassing agents continues to be hampered by a number of practical limitations, including the need for refrigerated storage of the agent and its recon...

2017
Angiola Rocino Massimo Franchini Antonio Coppola

The development of alloantibodies neutralising therapeutically administered factor (F) VIII/IX (inhibitors) is currently the most severe complication of the treatment of haemophilia. When persistent and at a high titre, inhibitors preclude the standard replacement treatment with FVIII/FIX concentrates, making patients' management challenging. Indeed, the efficacy of bypassing agents, i.e., acti...

Journal: :Blood advances 2017
Craig D Seaman Margaret V Ragni

Sequential bypassing agents may be a safe and effective treatment during major orthopedic surgery in hemophilia patients with inhibitors.

2017
Sandra Horning

Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine ● HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents ● All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate by 79% compared to prior prophylactic bypassing age...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید